Heartbeam Inc (BEAT) Stock Analysis
Verdict: AVOID
FDA Breakthrough status boosts BEAT's 3D ECG narrative, but a 3.75-month cash runway ($4.38M cash vs $14M annual burn) makes dilution imminent.
Investment score: 31/100
Analysis as of
Is Heartbeam Inc stock worth reviewing? AI model thesis
The model recommends AVOID on BEAT due to an imminent cash crunch (~3.75 months runway) and mandatory dilution risk, overriding short-term FDA news sentiment.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 45/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Heartbeam Inc opportunities and risks
What speaks for BEAT
- FDA Breakthrough Device Designation accelerates trial review
What speaks against BEAT
- Critical cash runway depletion under 4 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BEAT | n/a | 0.0x | n/a | 0.0% | 0.0% | -38.6% |
| POCI | n/a | 1.5x | n/a | 17.2% | -11.5% | -4.1% |
| SRTS | n/a | 2.7x | n/a | 36.4% | -88.5% | -14.5% |
| CVRX | n/a | 0.7x | n/a | 86.6% | -84.9% | -99.2% |
| SNWV | 2.8x | 0.9x | 2.7x | 75.2% | 32.6% | 15.3% |
| QTI | n/a | 1.3x | n/a | 39.6% | -65.3% | -35.4% |
| Peer median | n/a | 1.3x | n/a | 39.6% | -65.3% | -14.5% |
Frequently asked questions about Heartbeam Inc (BEAT)
Is BEAT stock a good investment?
The cached TradeMates AI model rates Heartbeam Inc as AVOID with an investment score of 31/100. The model recommends AVOID on BEAT due to an imminent cash crunch (~3.75 months runway) and mandatory dilution risk, overriding short-term FDA news sentiment. This is algorithmic model output, not personal investment advice.
Is BEAT stock a buy?
The TradeMates model verdict for BEAT is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.